Clinical Characteristic and Hematologic Responses to Imatinib in Patients with Chronic Phase Myeloid Leukemia (CML) at Cipto Mangunkusumo Hospital  

Oleh:

Reksodiputro, Ary H. ; Syafei, Syafrizal ; Prayogo, Nugroho

Jenis: Article from Journal - ilmiah nasional - terakreditasi DIKTI
Dalam koleksi: Acta Medica Indonesiana vol. 42 no. 01 (Jan. 2010), page 2-5.
Topik: clinical characteristic of patients with chronic phase CML; Imatinib; hematologic response
Fulltext: 2-5.pdf (41.12KB)

Ketersediaan

Perpustakaan FK Nomor Panggil: A02.K.02 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

Aim: to analyze the clinical characteristics of patients with chronic phase CML and evaluate complete hematologic responses (CHR) and overall survival (OS) after treatment with Imatinib. Methods: this is a cross sectional study using retrospective medical record of patients with chromosome Philadelphia positive and/or BCR-ABL positive chronic phase CML at the polyclinic of Teratai Department of Internal Medicine Cipto Mangunkusumo National Hospital during 2003-2008. In a period of 6 years, we included 53 patients with chromosome Philadelphia positive and/or BCR-ABL positive chronic phase CML. Patients were administered Imatinib 400 mg daily and then evaluation of clinical characteristics and complete blood count + differential count were performed every 2 weeks until CHR achieved at 3 months as defined by white cells count <10.000/mm3, platelet count <450.000/mm3, and non palpable spleen. Results: the median age was 37 years (16-67 years). Males were slightly more frequent than females (29 v.s. 24) with ratio of 1.2: 1. Thirty three percent of patients had splenomegaly. The vast majority (60%) of patients had previous treatment with Hydroxyurea. The laboratory features were: median of hemoglobin level was 10.0 g/dL (6.3-16.6 g/dl.), median of white-cell count was 13.300/uL (l900-621.000/uL), and median of platelet count was 424.000/uL (108. 000-4.400. OOO/uL). Median of basophils was 1.6% (0%-20%) and 88% of patients had <5% blasts in bone marrow. Conclusion: A CHR was achieved in 74% of patients and overall survival during the study was 66%. The most common adverse events were: nausea, myalgia, hypopigmentation of the skin, anemia, thrombocytopenia, and neutropenia.

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali